Share

April 24, 2012; 78 (17) Articles

Survival in MS

A randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial

D.S. Goodin, A.T. Reder, G.C. Ebers, G. Cutter, M. Kremenchutzky, J. Oger, D. Langdon, M. Rametta, K. Beckmann, T.M. DeSimone, V. Knappertz
First published April 11, 2012, DOI: https://doi.org/10.1212/WNL.0b013e3182535cf6
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1854

Share

Article Information

vol. 78 no. 17 1315-1322
DOI: 
https://doi.org/10.1212/WNL.0b013e3182535cf6
PubMed: 
22496198
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received June 8, 2011
  • Accepted December 14, 2011
  • First Published April 11, 2012.

Article Versions

Copyright & Usage: 
Copyright © 2012 by AAN Enterprises, Inc.

Author Disclosures

    1. D.S. Goodin, MD*,
    2. A.T. Reder, MD*,
    3. G.C. Ebers, MD,
    4. G. Cutter, PhD,
    5. M. Kremenchutzky, MD,
    6. J. Oger, MD,
    7. D. Langdon, PhD,
    8. M. Rametta, DO,
    9. K. Beckmann, MSc,
    10. T.M. DeSimone, PhD and
    11. V. Knappertz, MD
  1. D.S. Goodin, MD*,
    2. Scientific Advisory Boards:

    1. Bayer Schering Pharma; Merck Serono

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Occasional community lectures, symposia and/or academic talks sponsored by; Bayer Schering Pharma; Teva Neuroscience; Merck Serono, and; Novartis. In many cases, travel costs were reimbursed.

    Editorial Boards:

    1. International MS Journal, Editorial Board, 2000-2009 Speakers’ Bureaus:; Bayer Schering Pharma

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Bayer Schering; Novartis

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. I have served as an expert witness on various neurologic topics, 2008-2009

  2. A.T. Reder, MD*,
    3. Scientific Advisory Boards:

    1. Abbott; ImmunoScience, Inc.; AstraZeneca; Merck Serono; Athena Diagnostics, Inc.; Sanofi- Aventis; Bayer Schering Pharma; Biogen Idec; BioMS Medical; Blue Cross Blue Shield; Boehringer Ingelheim; Caremark Rx; Centocor Ortho Biotech Inc.; Cephalon, Inc.; Connetics Corp.; CroMedica Global Inc.; Eli Lilly and Company; Elan Corporation; Genentech, Inc.; Genzyme Corporation; GlaxoSmithKline; Hoechst Marion Roussel Canada Research, Inc.; Roche; Immunex Corporation; Institute for Health Care Quality; Johnson & Johnson; Yale University; Barrow Neurological Institute; National Multiple Sclerosis Society & Paralyzed Veterans of America; Neurocrine Biosciences; Novartis; Parke-Davis; Pfizer Inc.; Pharmacia & Upjohn; Protein Design Labs, Inc.; Quantum Biotechnologies, Inc.; Quintiles, Inc.; EMD Serono, Inc., (39 Sention, Inc.; Smith Kline- Beecham; Specialized Therapeutics (a division of Berlipharm, Inc.); Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Abbott; ImmunoScience, Inc.; AstraZeneca; Merck Serono; Athena Diagnostics, Inc.; Sanofi- Aventis; Bayer Schering Pharma; Biogen Idec; BioMS Medical; Blue Cross Blue Shield; Boehringer Ingelheim; Caremark Rx; Centocor Ortho Biotech Inc.; Cephalon, Inc.; Connetics Corp.; CroMedica Global Inc.; Eli Lilly and Company; Elan Corporation; Genentech, Inc.; Genzyme Corporation; GlaxoSmithKline; Hoechst Marion Roussel Canada Research, Inc.; Roche; Immunex Corporation; Institute for Health Care Quality; Johnson & Johnson; Yale University; Barrow Neurological Institute; National Multiple Sclerosis Society & Paralyzed Veterans of America; Neurocrine Biosciences; Novartis; Parke-Davis; Pfizer Inc.; Pharmacia & Upjohn; Protein Design Labs, Inc.; Quantum Biotechnologies, Inc.; Quintiles, Inc.; EMD Serono, Inc., (39 Sention, Inc.; Smith Kline- Beecham; Specialized Therapeutics (a division of Berlipharm, Inc.); Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd.

    Editorial Boards:

    1. Medlink/Neurobase Editorial Board, Arbor Publishing Corporation, San Diego, CA, 1999-Present; Turkish Journal of Medical Sciences, Editorial Board, 2001- present; Türk Nöroloji Dergisi (Turkish Journal of Neurology), Editorial Board, 2004-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Abbott; ImmunoScience, Inc.; AstraZeneca; Merck Serono; Athena Diagnostics, Inc.; Sanofi- Aventis; Bayer Schering Pharma; Biogen Idec; BioMS Medical; Blue Cross Blue Shield; Boehringer Ingelheim; Caremark Rx; Centocor Ortho Biotech Inc.; Cephalon, Inc.; Connetics Corp.; CroMedica Global Inc.; Eli Lilly and Company; Elan Corporation; Genentech, Inc.; Genzyme Corporation; GlaxoSmithKline; Hoechst Marion Roussel Canada Research, Inc.; Roche; Immunex Corporation; Institute for Health Care Quality; Johnson & Johnson; Yale University; Barrow Neurological Institute; National Multiple Sclerosis Society & Paralyzed Veterans of America; Neurocrine Biosciences; Novartis; Parke-Davis; Pfizer Inc.; Pharmacia & Upjohn; Protein Design Labs, Inc.; Quantum Biotechnologies, Inc.; Quintiles, Inc.; EMD Serono, Inc., (39 Sention, Inc.; Smith Kline- Beecham; Specialized Therapeutics (a division of Berlipharm, Inc.); Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd.

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Novartis; BioMS Medical; Eli Lilly and Company; Teva Pharmaceutical Industries Ltd.; Bayer Schering Pharma; EMD Serono, Inc.; Pfizer Inc.; Genentech, Inc.; Biogen Idec

    Research Support, Government Entities:

    1. NIH/NINDS RO1 NS 051591, Site PI; NIH 1 K24 RR021948, PI

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. the National MS Society; the Brain Research Foundation; the American Academy of Allergy & Immunology; Howard Hughes Foundation; Egypt Arab Republic Peace Fellowship; Turkish Ministry of Defense Fellowship Award; the State of Illinois

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. G.C. Ebers, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Bayer HealthCare Pharmaceuticals, funding for travel to meetings; Sanofi Aventis, speaker honorarium

    Editorial Boards:

    1. International MS Journal, Editorial Board, present; Multiple Sclerosis, Editorial Board, present; BMC Medical Genetics, Section Editor, 2010-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Biopartners; Bayer Healthcare Pharmaceuticals; Howrey LLP; Heron Health

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Bayer Schering Pharma

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. MS Society of Canada Scientific Research Foundation, 2008-2011

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. I prepared 4 medico-legal reports, 2009-2011

  4. G. Cutter, PhD,
    5. Scientific Advisory Boards:

    1. Participation of Data and Safety Monitoring Committees:; Sanofi-Aventis; Cleveland Clinic; Daichi- Sankyo; GlaxoSmithKline; Genmab Biopharmaceuticals; Eli Lilly; Medivation; Ono Pharmaceuticals; PTC Therapeutics; Teva; Vivus; Univ of Penn; NHLBI; NINDS; NMSS Consulting, Speaking fees & Advisory Boards:; Alexion; Bayhill; Bayer; Novartis; Consortium of MS Centers (grant); Klein-Buendel Incorporated; Peptimmune; Somnus Pharmaceuticals; Sandoz; Teva pharmaceuticals; UTSouthwestern; Visioneering Technologies, Inc

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Consortium of MS Centers, speaker honoraria; Bayer, speaker honoraria

    Editorial Boards:

    1. Multiple Sclerosis, Editorial Board, 2010-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Consulting, Speaking fees & Advisory Boards:; Alexion; Bayhill; Bayer; Novartis; Consortium of MS Centers (grant); Klein-Buendel Incorporated; Peptimmune; Somnus Pharmaceuticals; Sandoz; Teva pharmaceuticals; UTSouthwestern; Visioneering Technologies, Inc

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NINDS Grant with Multiple Sclerosis as the patient population

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH/NINDS 5U01NS042685-06, PI, 2005-2015; NIH/NIDDK 1P30 DK079337, Co-I, 2008-2013; NIH/NINDS U01 NS45719-01A1, Co-I and Director of the Statistical and Data Management Center, 2003-2012; NIH/NIAID HHSN272201000023C, Co-I, 2010-2015; NIH/NIAIDS 5P30- A1027767, Co-I, 2009-2014; NMSS, Co-I, 2009-2013; NIH/NCRR 3UL1RR025777, Co-I, 2009-2011; NIH/NHLBI 5P50HL084923, Director of Coordinating Center, 2007-2012; NIH/NIA 2R01AG021927-06A1, Co-I, 2010-2015; NIH/NICHHD 1R01HD064729-01A1, Investigator/DCC PI, 2010- 2014; NIH/NIDDKD 2P30DK074038-06, Co-I, 2010-2015; CONSORTIUM OF MULTIPLE SCLEROSIS CENTERS 000352886, Director of Data Center, 2009-open; NIH/NIDDK 1R01DK078826, 2009-2012; NIH/NINDS 5T32NS054584-05, 2011-2012; NIH - UNIVERSITY OF SOUTHERN CALIFORNIA H48487-01, 2011-2012; NIH/NHLBI 1U01HL102235-01A1, 2010–2013

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Consortium of MS Centers

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. M. Kremenchutzky, MD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Funding for travel from; Biogen; Bayer; Teva

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Biogen; Bayer; Teva; Sanofi; Novartis; Serono

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Genzyme; Cell Gene; Biogen; Bayer; Teva; Sanofi; Novartis; Serono

    Research Support, Government Entities:

    1. CIHR

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. MS Society of Canada

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. J. Oger, MD,
    7. Scientific Advisory Boards:

    1. Advisory Board for; Biogen Idec; Bayer; Novartis; DSMB for an investigator initiated trial on MS

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Multiple Sclerosis Journal, Editorial Board, 2000- 2011

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. research grant from Bayer on the matter of neutralizing antibodies to Interferons (NABs) received by UBC.; fees for NAB laboratory services from the Medical Services of British Columbia; fee for NAB laboratory services from Cinnagen

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. D. Langdon, PhD,
    8. Scientific Advisory Boards:

    1. Roche; Merck-Serono; Bayer; Novartis; Vertex

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Presenting at scientific conferences:; Bayer; Novartis; Sanofi-Aventis; Serono Symposia

    Editorial Boards:

    1. Multiple Sclerosis and Related Disorders,Psychology and Fatigue Section Editor, 2011-present; European Neurological Review, Editorial Board, 2010-present I do not receive any compensation for these journal positions

    Patents:

    1. NONE

    Publishing Royalties:

    1. Verbal and Spatial Reasoning Test, Psychology Press, 1995- present

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Bayer (Consultancy fees paid into my university charity account) Speakers’ Bureaus:; Serono; Bayer; Sanofi-Aventis; Novartis; Serono Symposia

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Bayer, unrestricted educational grant for PhD studentship, 2005-8; Bayer, research contract to collect cognition data in 21Y LTF study, 2010-11

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. RHUL/SGUL, PhD studentship, 2006-9

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. M. Rametta, DO,
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. K. Beckmann, MSc,
    10. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. T.M. DeSimone, PhD and
    11. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. I am a medical writer at PAREXEL, which was funded by Bayer HealthCare Pharmaceuticals to assist with the development of this manuscript.

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. V. Knappertz, MD
    12. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Bayer Healthcare Pharmaceuticals, Global Medical Affairs, Multiple Sclerosis

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (D.S.G.), University of California, San Francisco; Department of Neurology (A.T.R.), University of Chicago, IL; University Department of Clinical Neurology (G.C.E.), John Radcliffe Hospital, Oxford, UK; Department of Biostatistics (G.C.), University of Alabama School of Public Health, Birmingham; London Health Sciences Center (M.K.), London, Canada; Neuroimmunology Laboratories and Multiple Sclerosis Clinic (J.O.), University of British Columbia, Vancouver, Canada; Department of Psychology (D.L.), Royal Holloway, University of London, Surrey, UK; Bayer HealthCare Pharmaceuticals (M.R.), Wayne, NJ; Bayer HealthCare Pharmaceuticals (K.B.), Berlin, Germany; PAREXEL (T.M.D.), Hackensack, NJ; Bayer HealthCare Pharmaceuticals (V.K.), Montville, NJ; and Heinrich-Heine-Universität (V.K.), Düsseldorf, Germany.
  1. Correspondence & reprint requests to Dr. Goodin: douglas.goodin{at}ucsf.edu
View Full Text

Article usage

Article usage: April 2012 to September 2019

AbstractFullPdfSource
Apr 2012188854206Highwire
May 201277347103Highwire
Jun 20122772445Highwire
Jul 20122184548Highwire
Aug 20122183326Highwire
Sep 20122632029Highwire
Oct 20122363443Highwire
Nov 20121192430Highwire
Dec 20121821416Highwire
Jan 20131644545Highwire
Feb 20131031743Highwire
Mar 2013712016Highwire
Apr 2013741918Highwire
May 2013511218Highwire
Jun 20137599Highwire
Jul 2013561219Highwire
Aug 2013411114Highwire
Sep 2013461314Highwire
Oct 2013601722Highwire
Nov 2013701114Highwire
Dec 20135244Highwire
Jan 201450711Highwire
Jan 201405029pmc
Feb 20143076Highwire
Mar 20144847Highwire
Apr 201446146Highwire
May 201439513Highwire
Jun 20141998Highwire
Jul 20144023Highwire
Aug 20141768Highwire
Sep 20142987Highwire
Oct 2014361111Highwire
Nov 20142200Highwire
Dec 20144124Highwire
Jan 20153875Highwire
Jan 201504022pmc
Feb 20154623Highwire
Feb 201504031pmc
Mar 201552912Highwire
Mar 201506324pmc
Apr 20152777Highwire
Apr 201504718pmc
May 20154447Highwire
May 201503717pmc
Jun 20153656Highwire
Jun 201505819pmc
Jul 20152711Highwire
Jul 201502211pmc
Aug 20152666Highwire
Aug 201504223pmc
Sep 201546107Highwire
Sep 201503821pmc
Oct 20152466Highwire
Oct 201505419pmc
Nov 20153965Highwire
Nov 201503915pmc
Dec 20153541Highwire
Dec 201503720pmc
Jan 20161623Highwire
Jan 201604316pmc
Feb 20163657Highwire
Feb 201607615pmc
Mar 20162755Highwire
Mar 201606722pmc
Apr 20162965Highwire
Apr 201603917pmc
May 20162622Highwire
May 201605227pmc
Jun 20163954Highwire
Jun 201603316pmc
Jul 20163032Highwire
Jul 201606011pmc
Aug 20163025Highwire
Aug 201606714pmc
Sep 20162122Highwire
Sep 201606211pmc
Oct 20162811Highwire
Oct 20160309pmc
Nov 20163112Highwire
Nov 201604216pmc
Dec 20162200Highwire
Dec 201602712pmc
Jan 20172011Highwire
Jan 201702813pmc
Feb 20172112Highwire
Feb 201702711pmc
Mar 20171802Highwire
Mar 201703815pmc
Apr 20174033Highwire
Apr 2017111926pmc
May 20172422Highwire
May 2017123538pmc
Jun 20171254Highwire
Jun 2017132633pmc
Jul 2017911Highwire
Jul 2017122536pmc
Aug 2017934Highwire
Aug 201792628pmc
Sep 20172001Highwire
Sep 2017252636pmc
Oct 20171622Highwire
Oct 2017143034pmc
Nov 20171833Highwire
Nov 2017232125pmc
Dec 20173000Highwire
Jan 20182295Highwire
Feb 20181410Highwire
Mar 20182531Highwire
Apr 20182020Highwire
Apr 2018132629pmc
May 20182722Highwire
Jun 20182057Highwire
Jun 201871817pmc
Jul 20182494Highwire
Aug 20182121Highwire
Aug 2018102024pmc
Sep 20183022Highwire
Oct 20182044Highwire
Nov 20182253Highwire
Dec 20184962Highwire
Jan 2019109102Highwire
Feb 20192711Highwire
Mar 20191610Highwire
Apr 20193700Highwire
May 20193720Highwire
Jun 20191900Highwire
Jul 20191923Highwire
Aug 20192812Highwire
Sep 20193700Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me